KIMMTRAK recommended for funding by NICE for uveal melanoma patients - PharmaTimes Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence

#KIMMTRAK #tebentafusp #immunotherapy #biologics #NHSfunding #optics #Ophthalmology #Uvealmelanoma #eyecancer#Immunocore #TCR @england.nhs.uk #NICE #mUM #rarediseases #oncology #cancer #Tcellreceptorimmunotherapy #ImmTAC #ImmTACtechnologyplatform
pharmatimes.com/news/kimmtra...